Nektar Therapeutics/$NKTR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Ticker
$NKTR
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
61
ISIN
US6402683063
Website
NKTR Metrics
BasicAdvanced
$368M
-
-$9.52
0.56
-
Price and volume
Market cap
$368M
Beta
0.56
52-week high
$37.38
52-week low
$7.99
Financial strength
Current ratio
3.241
Quick ratio
3.107
Long term debt to equity
1,199.716
Total debt to equity
1,358.706
Interest coverage (TTM)
-5.07%
Profitability
EBITDA (TTM)
-135.95
Gross margin (TTM)
74.61%
Net profit margin (TTM)
-152.49%
Operating margin (TTM)
-160.27%
Effective tax rate (TTM)
0.11%
Revenue per employee (TTM)
$1,430,000
Management effectiveness
Return on assets (TTM)
-26.80%
Return on equity (TTM)
-189.46%
Valuation
Price to revenue (TTM)
4.756
Price to book
30.38
Price to tangible book (TTM)
26.8
Price to free cash flow (TTM)
-2.329
Free cash flow yield (TTM)
-42.94%
Free cash flow per share (TTM)
-1,274.55%
Growth
Revenue change (TTM)
-3.24%
Earnings per share change (TTM)
-30.92%
3-year revenue growth (CAGR)
-5.41%
10-year revenue growth (CAGR)
-11.31%
3-year earnings per share growth (CAGR)
-38.01%
10-year earnings per share growth (CAGR)
12.35%
Bulls say / Bears say
B. Riley Securities initiated coverage of Nektar Therapeutics with a 'Buy' recommendation and a price target of $4.00, suggesting a potential upside of 250.88% from the current price. (marketbeat.com)
Nektar Therapeutics reported a net income of $7.26 million for the quarter ended December 31, 2024, marking a significant improvement from a net loss in the same quarter the previous year. (tradingview.com)
The company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata, indicating progress in its clinical pipeline. (prnewswire.com)
Nektar Therapeutics reported a quarterly revenue of $29.18 million, missing analyst expectations of $29.86 million, indicating potential challenges in meeting revenue targets. (tradingview.com)
The company's stock has declined by 38.8% since its last earnings report, reflecting investor concerns over its financial performance and future prospects. (stockinvest.us)
Barclays PLC reduced its holdings in Nektar Therapeutics by 9.1% during the fourth quarter, suggesting decreased institutional confidence in the company's stock. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 25 Jun 2025.
NKTR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nektar Therapeutics stock?
Nektar Therapeutics (NKTR) has a market cap of $368M as of June 27, 2025.
What is the P/E ratio for Nektar Therapeutics stock?
The price to earnings (P/E) ratio for Nektar Therapeutics (NKTR) stock is 0 as of June 27, 2025.
Does Nektar Therapeutics stock pay dividends?
No, Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Nektar Therapeutics dividend payment date?
Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders.
What is the beta indicator for Nektar Therapeutics?
Nektar Therapeutics (NKTR) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.